2024 Senate Resolution 117

Whereas, Many people with serious mental illnesses, such as bipolar disorder, major depressive disorder, schizophrenia and other schizoaffective disorders, or gastrointestinal disorders (gastroparesis, upset stomach, nausea, and vomiting) may be treated with medications that work as dopamine receptor blocking agents, including antipsychotics and antiemetics; and

Whereas, While ongoing treatment with these medications can be necessary, prolonged use is associated with tardive dyskinesia (TD), an involuntary movement disorder that is characterized by uncontrollable, abnormal, and repetitive movements of the face, torso, limbs, fingers, or toes; and

Whereas, Even mild symptoms of TD can impact people physically, socially, and emotionally; and

Whereas, It is estimated that TD affects 600,000 people in the United States, and approximately 65 percent of people with TD have not been diagnosed, making it important to raise awareness about the symptoms; and

Whereas, It is essential that people taking these medications be monitored for TD by a healthcare provider. Regular screening for TD is recommended by the American Psychiatric Association; and

Whereas, Clinical research has led to approval of treatments for adults with TD by the United States Food and Drug Administration, and recognition and treatment of TD can make a positive impact in the lives of many people experiencing psychotic and mood disorders; and

Whereas, We take this time to raise awareness and understanding of TD among the public and medical community; now, therefore, be it

Resolved by the Senate, That the members of this legislative body designate May 5-11, 2024, as Tardive Dyskinesia Awareness Week; and be it further

Resolved, That we encourage anyone experiencing uncontrollable, abnormal, and repetitive movements to consult their healthcare provider regarding their symptoms.